Yale University (New Haven) psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Yale University is listed with 31 registered studies counted here, in New Haven, United States. By compound: 7 psilocybin, 2 MDMA, 1 DMT and 21 ketamine. By registry status: 7 recruiting, 2 not yet recruiting, 3 active, not recruiting, 13 completed, 5 terminated and 1 withdrawn. By phase: 2 early phase 1, 11 phase 1, 12 phase 2, 1 phase 4 and 5 not applicable. Reported start years run from 2009 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 31 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 7 |
| MDMA | 2 |
| DMT | 1 |
| Ketamine | 21 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 7 | 23% |
| Not yet recruiting | 2 | 6% |
| Active, not recruiting | 3 | 10% |
| Completed | 13 | 42% |
| Terminated | 5 | 16% |
| Withdrawn | 1 | 3% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 2 | 6% |
| Phase 1 | 11 | 35% |
| Phase 2 | 12 | 39% |
| Phase 4 | 1 | 3% |
| Not applicable | 5 | 16% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| The Effects of Psilocybin on Social Connectedness | NCT07693153 | Not yet recruiting | Phase 1 | 2026-08-31 | Psilocybin |
| Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain | NCT07306364 | Not yet recruiting | Phase 2 | 2026-06-01 | Psilocybin |
| The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease | NCT07610369 | Recruiting | Phase 2 | 2026-05-01 | Psilocybin |
| Imaging Depression in Parkinson's Disease | NCT06402955 | Recruiting | Phase 2 | 2025-12-01 | Ketamine |
| MDMA in Borderline Personality Disorder | NCT06683014 | Recruiting | Phase 2 | 2025-09-05 | MDMA |
| The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD) | NCT06070649 | Recruiting | Phase 1 | 2025-08-04 | DMT |
| Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) | NCT06160284 | Recruiting | Phase 1 | 2025-05-28 | Psilocybin |
| Open-Label Psilocybin Study in Transdiagnostic Population | NCT06442423 | Recruiting | Phase 1 | 2024-10-17 | Psilocybin |
| Role Of Non-Specific Effects in The Treatment of Depression With Esketamine | NCT05910775 | Terminated | Not applicable | 2024-07-13 | Ketamine |
| Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatment | NCT06139016 | Completed | Not applicable | 2024-07-11 | Ketamine |
| The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD. | NCT03752918 | Withdrawn | Phase 1 | 2024-05-01 | MDMA |
| Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response | NCT05915013 | Recruiting | Phase 1 | 2023-09-07 | Ketamine |
| Enhancing Week-long Psychological Treatment for PTSD With Ketamine | NCT05737693 | Active, not recruiting | Phase 2 | 2023-08-21 | Ketamine |
| Effects of Repeated Psilocybin Dosing in OCD | NCT05370911 | Active, not recruiting | Phase 1 | 2023-07-20 | Psilocybin |
| Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine | NCT04613453 | Terminated | Phase 2 | 2022-01-21 | Ketamine |
| Ketamine for the Treatment of Depression in Parkinson's Disease | NCT04944017 | Completed | Phase 2 | 2021-11-23 | Ketamine |
| Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy | NCT03889756 | Terminated | Phase 2 | 2019-07-17 | Ketamine |
| Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial | NCT03367533 | Completed | Phase 1 | 2018-11-29 | Ketamine |
| Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study. | NCT03356483 | Completed | Phase 1 | 2018-11-13 | Psilocybin |
| Ketamine in Borderline Personality Disorder | NCT03395314 | Terminated | Phase 2 | 2018-02-15 | Ketamine |
| Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression | NCT03027362 | Completed | Not applicable | 2017-01-01 | Ketamine |
| Imaging SV2A in Mood Disorders | NCT02734602 | Active, not recruiting | Not applicable | 2016-04-01 | Ketamine |
| Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects | NCT02487485 | Completed | Phase 2 | 2016-03-01 | Ketamine |
| Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy | NCT02727998 | Terminated | Phase 2 | 2015-12-01 | Ketamine |
| Ketamine Infusion for Adolescent Depression and Anxiety | NCT02579928 | Completed | Phase 4 | 2015-10-01 | Ketamine |
| Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine | NCT02289248 | Completed | Phase 1 | 2015-02-01 | Ketamine |
| Ketamine Infusion for Social Anxiety Disorder | NCT02083926 | Completed | Early Phase 1 | 2015-01-02 | Ketamine |
| Characterizing Clinical and Pharmacological Neuroimaging Biomarkers | NCT03842800 | Completed | Early Phase 1 | 2013-04-01 | Ketamine |
| PET Imaging of mGLuR5 With Drug Challenge | NCT01691092 | Completed | Not applicable | 2012-06-01 | Ketamine |
| Ketamine for Low Mood States in the ER | NCT01209845 | Completed | Phase 1 | 2010-04-01 | Ketamine |
| Ketamine Infusion for Obsessive-Compulsive Disorder | NCT01349231 | Completed | Phase 2 | 2009-02-01 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | DMT | Ketamine